Clinical Trial Update: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CLIC-1901 for relapsed/refractory CD19-positive hematologic malignancies (Phase 1/Phase 2), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CLIC-1901

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING